NCT06917079

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers

This Phase 1a/1b open-label research study is an early-stage study designed to test a new experimental drug called BBO-11818 in people with advanced cancers that have KRAS gene mutations. KRAS mutations are among the most common genetic changes driving cancer growth, especially in tumors like lung, colorectal, and pancreatic cancers. Researchers are measuring how the drug behaves in the body—how it’s absorbed, distributed, and cleared—and whether it can shrink or control tumors in participants whose cancers no longer respond to standard therapy. By targeting KRAS-driven pathways, BBO-11818 aims to block cancer cell growth directly and possibly make tumor cells more sensitive to other treatments. This trial marks one of the first steps in determining whether BBO-11818 could become a new targeted option for patients with hard-to-treat KRAS-mutant cancers.

Open Label: Patients know which treatments are being given to them

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06917079

Clinical Trial Site: Columbia

To see all available clinical trials click here.